ReviewCurrent heart failure reports2020
Epitranscriptomics in the Heart: a Focus on m
Review in Current heart failure reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Emerging Role of Epitranscriptomics in Diabetes Mellitus and Its Complications.Frontiers in endocrinology · 2022Pooled it
- PIWI-Interacting RNAs in Cardiovascular Disease: From Epigenetic Regulators to Clinical Biomarkers and Therapeutic Targets.Reviews in cardiovascular medicine · 2026Review
- Epitranscriptomic regulation of HIF-1: bidirectional regulatory pathways.Molecular medicine (Cambridge, Mass.) · 2025Review
- ALKBH5 induces fibroblast-to-myofibroblast transformation during hypoxia to protect against cardiac rupture after myocardial infarction.Journal of advanced research · 2024Article
- Epitranscriptomic Regulations in the Heart.Physiological research · 2024Review
- The m6 RNA methylation regulator KIAA1429 is associated with autophagy-mediated drug resistance in lung cancer.FASEB bioAdvances · 2024Article
- Article
- RNA modification mEpigenetics · 2023Review
- Article
- The role of mFrontiers in endocrinology · 2023Review
- N6-methyladenosine (m6A) RNA modification in the pathophysiology of heart failure: a narrative review.Cardiovascular diagnosis and therapy · 2022Review
- Targeting Epigenetic Regulation of Cardiomyocytes through Development for Therapeutic Cardiac Regeneration after Heart Failure.International journal of molecular sciences · 2022Review
- Role of epigenetic transgenerational inheritance in generational toxicology.Environmental epigenetics · 2022Review
- Epitranscriptomics of cardiovascular diseases (Review).International journal of molecular medicine · 2022Review
- Epitranscriptomics of Ischemic Heart Disease-The IHD-EPITRAN Study Design and Objectives.International journal of molecular sciences · 2021Article
- NCell death discovery · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewPost-transcriptional modifications are key regulators of gene expression that allow the cell to respond to environmental stimuli. The most abundant internal mRNA modification is N6-methyladenosine (m RECENT
findingsStudies have primarily relied on gain and loss of function models for the enzymes responsible for adding and removing the m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.